279 related articles for article (PubMed ID: 17368973)
41. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
42. New products and regimens (since 2003).
Panay N
Climacteric; 2007 Oct; 10 Suppl 2():109-14. PubMed ID: 17882685
[TBL] [Abstract][Full Text] [Related]
43. Pharmacologic characteristics of progestins used for contraception and hormone replacement therapy, including new transdermal technologies.
Burkman RT
Am J Manag Care; 2001 Nov; 7(18 Suppl):S571-4. PubMed ID: 11727395
[TBL] [Abstract][Full Text] [Related]
44. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
46. Innovations in contraception: a review.
Zurawin RK; Ayensu-Coker L
Clin Obstet Gynecol; 2007 Jun; 50(2):425-39. PubMed ID: 17513928
[TBL] [Abstract][Full Text] [Related]
47. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
48. One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu.
Pluchino N; Ninni F; Stomati M; Freschi L; Casarosa E; Valentino V; Luisi S; Genazzani AD; Potì E; Genazzani AR
Maturitas; 2008 Apr; 59(4):293-303. PubMed ID: 18394829
[TBL] [Abstract][Full Text] [Related]
49. Long-term use of the levonorgestrel-releasing intrauterine system.
Inki P
Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611
[TBL] [Abstract][Full Text] [Related]
50. Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women.
Hermenegildo C; Oviedo PJ; Laguna A; García-Pérez MA; Tarín JJ; Cano A
Menopause; 2008; 15(4 Pt 1):714-7. PubMed ID: 18340278
[TBL] [Abstract][Full Text] [Related]
51. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
Krapf JM; Simon JA
Maturitas; 2009 Jul; 63(3):213-9. PubMed ID: 19487090
[TBL] [Abstract][Full Text] [Related]
52. [Hormone replacement therapy in postmenopausal women: all the treatments are not the same].
Ribot C; Trémollieres F
Gynecol Obstet Fertil; 2007 May; 35(5):388-97. PubMed ID: 17392010
[TBL] [Abstract][Full Text] [Related]
53. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
[TBL] [Abstract][Full Text] [Related]
54. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
Casanova G; Radavelli S; Lhullier F; Spritzer PM
Fertil Steril; 2009 Aug; 92(2):605-12. PubMed ID: 18706557
[TBL] [Abstract][Full Text] [Related]
55. New progestagens for contraceptive use.
Sitruk-Ware R
Hum Reprod Update; 2006; 12(2):169-78. PubMed ID: 16291771
[TBL] [Abstract][Full Text] [Related]
56. Hormone therapy and thromboembolic disease.
Battaglioli T; Martinelli I
Curr Opin Hematol; 2007 Sep; 14(5):488-93. PubMed ID: 17934355
[TBL] [Abstract][Full Text] [Related]
57. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
59. Zelrix: a novel transdermal formulation of sumatriptan.
Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
[TBL] [Abstract][Full Text] [Related]
60. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
